Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Bossé, Dominick; Ng, Tat Fong; Ahmad, Chaudhary E.; Al-Fakeeh, Ali; Alruzug, Ibrahim M; Biagi, James; Brierley, James D.; Chaudhury, Prosanto; Cleary, Sean P.; Colwell, Bruce; Cripps, C.; Dawson, Laura A.; Dorreen, M.; Ferland, E.; Galiatsatos, Polymnia; Girard, Sandrine; Gray, Samantha; Halwani, Fawaz; Kopek, Neil; Mahmud, Aamer; Martel, Guillaume; Robillard, Liliane; Samson, Benoît; Seal, Melanie; Siddiqui, J.; Sidéris, Lucas; Snow, Stephanie; Thirwell, M.; Vickers, Michael M.; Goodwin, Rachel; Goel, Rakesh; Hsu, Tina; Цветкова, Евдокия; Ward, Brian J.; Asmis, Tim

doi:10.3747/co.23.3394

Cited by 6 publications

(4 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 2018 American Association for the Study of Liver Diseases guideline includes EBRT as one of the locoregional therapy options for patients with T2 or T3 HCC without vascular involvement who are not candidates for resection or OLT 69 . Recommendations from the 2016 Eastern Canadian Gastrointestinal Cancer Consensus Conference included a role for SABR in treating CP‐A and selected B7 HCC patients who are not candidates for resection, OLT, or other locoregional curative options 70 . SABR was also considered an option for patients requiring bridging therapy to OLT if they were not candidates for thermal ablation or TACE.…”

Section: Guidelinesmentioning

confidence: 99%

“…69 Recommendations from the 2016 Eastern Canadian Gastrointestinal Cancer Consensus Conference included a role for SABR in treating CP-A and selected B7 HCC patients who are not candidates for resection, OLT, or other locoregional curative options. 70 SABR was also considered an option for patients requiring bridging therapy to OLT if they were not candidates for thermal ablation or TACE.…”

Section: Guidelinesmentioning

confidence: 99%

See 1 more Smart Citation

Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium

Shanker

Liu

Lee

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third most common cause of cancer-related death. Long-term prognosis remains poor with treatment options frequently limited by advanced tumor stage, tumor location, or underlying liver dysfunction. Stereotactic ablative body radiotherapy (SABR) utilizes technological advances to deliver highly precise, tumoricidal doses of radiation. There is an emerging body of literature on SABR in HCC demonstrating high rates of local control in the order of 80-90% at 3 years. SABR is associated with a low risk of radiation-induced liver disease or decompensation in appropriately selected HCC patients with compensated liver function and is now being incorporated into guidelines as an additional treatment option. This review outlines the emerging role of SABR in the multidisciplinary management of HCC and summarizes the current evidence for its use as an alternative ablative option for early-stage disease, as a bridge to transplant, and as palliation for advanced-stage disease. We outline specific considerations regarding patient selection, toxicities, and response assessment. Finally, we compare current international guidelines and recommendations for the use of SABR and summarize ongoing studies. Indications for stereotactic ablative body radiotherapy in hepatocellular carcinomaStereotactic ablative body radiotherapy has potential application across a broad range of indications from ablation of early-stage disease through to palliation of advanced-stage disease (Fig. 1). Key studies are summarized (Table 1). Figure 1 Potential indications for stereotactic radiotherapy in hepatocellular carcinoma according to Barcelona Clinic Liver Cancer stage. HCC, hepatocellular carcinoma; MVI, macrovascular invasion; OLT, orthotopic liver transplantation; RT, radiation therapy; SABR, stereotactic ablative body radiotherapy; TACE, transarterial chemoembolization; TARE, transarterial radioembolization. [Color figure can be viewed at wileyonlinelibrary.com] Stereotactic radiotherapy for HCC MD Shanker et al.

show abstract

Section: Guidelinesmentioning

confidence: 99%

Section: Guidelinesmentioning

confidence: 99%

Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium

Shanker

Liu

Lee

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Importantly, temsirolimus treatment has been widely associated with reactivation of latent Mtb infection among RCC patients. Also, progression of tumor was noted in these patients when temsirolimus was administered in combination with rifampicin, a first-line anti-TB drug (Bossé et al, 2016 ).…”

Section: Mtor Inhibitors As Potential Hdt For Tbmentioning

confidence: 99%

Harnessing the mTOR Pathway for Tuberculosis Treatment

Singh

Subbian

2018

Front. Microbiol.

View full text Add to dashboard Cite

Tuberculosis (TB) remains as one of the leading killer infectious diseases of humans. At present, the standard therapeutic regimen to treat TB comprised of multiple antibiotics administered for a minimum of six months. Although these drugs are useful in controlling TB burden globally, they have not eliminated the disease. In addition, the lengthy duration of treatment with multiple drugs contributes to patient non-compliance that can result in the development of drug resistant strains (MDR and XDR) of Mycobacterium tuberculosis (Mtb), the causative agent of TB. Therefore, new and improved therapeutic strategies are urgently needed for effective control of TB worldwide. The intracellular survival of Mtb is regarded as a cumulative effect of the host immune response and the bacterial ability to resist or subvert this response. When the host innate defensive system is manipulated by Mtb for its survival and dissemination, the host develops disease conditions that are hard to overcome. The host intrinsic factors also contributes to the poor efficacy of anti-mycobacterial drugs and to the emergence of drug resistance. Hence, strengthening the immune repertoire involved in combating Mtb through host-directed therapeutics (HDT) can be one of the approaches for effective bacterial killing and clearance of infection/disease. Recently, more scientific research has been focused toward HDT strategies that empowers host cells for effective killing of Mtb, reduce the duration of treatment and/or alleviates the development of MDR/XDR, since Mtb cannot develop resistance against a drug that targets the host cell function. Autophagy is a conserved cellular process critical for maintaining cellular integrity and function. Autophagy is regulated by multiple pathways that are either dependent or independent of mTOR (mechanistic target of rapamycin; a.k.a. mammalian target of rapamycin), a master regulatory molecules that impacts several cellular functions. In this review, we summarize the role of autophagy in Mtb pathogenesis, the mTOR pathway and, modulating the mTOR pathway with inhibitors as potential adjunctive HDT, in combination with standard anti-TB antibiotics, to improve the outcome of current TB treatment.

show abstract

“…In these cases, SBRT should only be used limitedly since there is too little data for esophagogastric tumors and metastases are often located close to organs at risk, as stated by Matsushita et al [117]. Thus, the Eastern Canadian gastrointestinal cancer consensus conference concluded that the aim of SBRT in the oligometastatic setting is limited to achieving local control and delaying progression [118]. It is important to recall that local radiotherapy is one specific option of tumor control for a limited duration, either postponing the palliative situation or leading to salvage resection.…”

Section: Prospective Diagnostic and Therapeutic Strategiesmentioning

confidence: 99%

Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach

Jung

Nienhüser

Schleußner

et al. 2020

IJMS

View full text Add to dashboard Cite

Gastric and esophageal cancers are dreaded malignancies, with a majority of patients presenting in either a locally advanced or metastatic state. Global incidences are rising and the overall prognosis remains poor. The concept of oligometastasis has been established for other tumor entities and is also proposed for upper gastrointestinal tract cancers. This review article explores metastasis mechanisms on the molecular level, specific to esophageal and gastric adenocarcinoma. Existing data and recent studies that deal with upper gastrointestinal tumors in the oligometastatic state are reviewed. Furthermore, current therapeutic targets in gastroesophageal cancers are presented and discussed. Finally, a perspective about future diagnostic and therapeutic strategies is given.

show abstract

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Cited by 6 publications

References 91 publications

Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium

Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium

Harnessing the mTOR Pathway for Tuberculosis Treatment

Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach

Contact Info

Product

Resources

About